Ildstad S T, Wren S M, Oh E, Hronakes M L
Department of Surgery, University of Pittsburgh, Pennsylvania 15261.
Transplantation. 1991 Jun;51(6):1262-7. doi: 10.1097/00007890-199106000-00022.
Mixed allogeneic reconstitution, in which a mixture of T-cell-depleted bone marrow of syngeneic host and allogeneic donor type is transplanted into a lethally irradiated recipient (A+B----A), results in mixed lymphopoietic chimerism with engraftment of a mixture of both host and donor bone marrow elements. Recipients are specifically tolerant to donor both in vitro and in vivo. Donor-specific skin grafts survive indefinitely when they are placed after full bone marrow repopulation at 28 days, while third-party grafts are rapidly rejected. To determine whether a delay of a month or more for full bone marrow repopulation is required before a donor-specific graft can be placed, we have now examined whether tolerance induction can be achieved if a graft is placed at the time of bone marrow transplantation. Permanent acceptance of donor-specific B10.BR skin grafts occurred when mixed allogeneic chimerism (B10+B10.BR----B10) was induced and a simultaneous allogeneic donor graft placed. In vitro, mixed reconstituted recipients were specifically tolerant to the B10.BR donor lymphoid cells but fully reactive to MHC-disparate third-party (BALB/c; H-2dd) when assessed by mixed lymphocyte reaction (MLR) and cell-mediated lympholysis (CML) assays. These data therefore indicate that a donor-specific graft placed at the time of mixed allogeneic reconstitution is permanently accepted without rejection. To determine whether an allogeneic skin graft alone without allogeneic bone marrow would be sufficient to induce tolerance, syngeneic reconstitution (B10----B10) was carried out, and a simultaneous B10.BR allogeneic skin graft placed. Although skin grafts were prolonged in all recipients, all grafts rejected when full lymphopoietic repopulation occurred at 28 days. Taken together, these data suggest that allogeneic donor bone marrow elements are required for the induction and maintenance of donor-specific transplantation tolerance and that allogeneic skin grafts alone are not sufficient for tolerance induction.
混合异体重建是将同基因宿主和异基因供体类型的T细胞去除的骨髓混合物移植到接受致死剂量照射的受体中(A+B→A),会导致混合淋巴细胞嵌合体的形成,宿主和供体骨髓成分均会植入。受体在体外和体内对供体具有特异性耐受性。当在28天骨髓完全重建后进行供体特异性皮肤移植时,移植皮片可长期存活,而第三方移植皮片则会迅速被排斥。为了确定在进行供体特异性移植之前是否需要延迟一个月或更长时间以实现完全骨髓重建,我们现在研究了在骨髓移植时进行移植是否能够诱导耐受性。当诱导混合异体嵌合体(B10+B10.BR→B10)并同时进行异体供体移植时,供体特异性B10.BR皮肤移植被永久接受。在体外,通过混合淋巴细胞反应(MLR)和细胞介导的淋巴细胞溶解(CML)试验评估,混合重建的受体对B10.BR供体淋巴细胞具有特异性耐受性,但对MHC不相容的第三方(BALB/c;H-2dd)具有完全反应性。因此,这些数据表明,在混合异体重建时进行的供体特异性移植可被永久接受而不被排斥。为了确定单独的异体皮肤移植而不进行异体骨髓移植是否足以诱导耐受性,进行了同基因重建(B10→B10),并同时进行B10.BR异体皮肤移植。尽管所有受体的皮肤移植存活时间都延长了,但当在28天出现完全淋巴细胞重建时,所有移植皮片均被排斥。综上所述,这些数据表明,异体供体骨髓成分是诱导和维持供体特异性移植耐受性所必需的,单独的异体皮肤移植不足以诱导耐受性。